ctDNA Pre-Radiation Predicts Oligometastatic NSCLC Survival

Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.

Related Keywords

Missouri ,United States ,Siteman Cancer Center ,London ,City Of ,United Kingdom ,Canada ,Washington University ,American ,Aadel Chaudhuri ,Rohannjm Correa ,Rabushka Fund ,Washington University School Of Medicine ,Alvin Sitemen Foundation ,London Health Sciences Center ,V Foundation ,Children Discovery Institute ,Melanoma Research Alliance ,Cancer Research Foundation ,Children Tumor Foundation ,American Society For Radiation Oncology ,American Society ,Radiation Oncology ,Washington University School ,Precision Oncology ,Discovery Institute ,Tumor Foundation ,Emerson Collective ,Tempus Labs ,Non Small Cell Lung Cancer ,Nsclc ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Liquid Biopsy ,Luid Biopsy ,Luid Phase Biopsy ,Cancer Blood Test ,Ancer Saliva Test ,Lood Biopsy ,Erum Biopsy ,Skin Cancer ,Alignant Skin Neoplasm ,Biopsy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Tumor ,Tissue ,Melanoma ,Malignant Melanoma ,Lung ,Plasma ,Triage ,